Evidence map›Paper›PMID 30125130›Full record

ArticleJournal of global oncology2018

Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women.

Sally N Adebamowo, Ayotunde Famooto, Eileen O Dareng, Oluwatoyosi Olawande, Olayinka Olaniyan, Richard Offiong, Clement A Adebamowo

Abstract read
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Human Papillomavirus infection in senegalese female sex workers.Papillomavirus research (Amsterdam, Netherlands) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sally N AdebamowoSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.
Ayotunde FamootoSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.
Eileen O DarengSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.
Oluwatoyosi OlawandeSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.
Olayinka OlaniyanSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.
Richard OffiongSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.
Clement A AdebamowoSally N. Adebamowo and Clement A. Adebamowo, University of Maryland School of Medicine, Baltimore, MD; Sally N. Adebamowo, Ayotunde Famooto, and Clement A. Adebamowo, Center for Bioethics and Research, Ibadan; Ayotunde Famooto and Oluwatoyosi Olawande, Institute of Human Virology Nigeria; Olayinka Olaniyan, National Hospital Abuja; Richard Offiong, University of Abuja Teaching Hospital, Abuja, Nigeria; Eileen O. Dareng, University of Cambridge, Cambridge, United Kingdom.

Funding

African Collaborative Center for Microbiome and Genomics Research (ACCME)U54HG006947 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ADEBAMOWO, CLEMENT ADEBAYO · 2013 to 2018
$5.7M
Capacity Development for Research into AIDS Associated malignancies (CADRE)D43CA153792 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI ADEBAMOWO, CLEMENT ADEBAYO · 2010 to 2013
$1.8M
NCI NIH HHS D43 CA153792NHGRI NIH HHS U54 HG006947
6 · The paper itself

Abstract

Purpose There is a dearth of data on clearance of cervical human papillomavirus (HPV) infection among women in West Africa. We examined the clearance of low-risk (lr) and high-risk (hr) cervical HPV infections, and the factors associated with these measures in HIV-negative and HIV-positive women. Methods We studied 630 Nigerian women involved in a study of HPV infection using short polymerase chain reaction fragment-10 assay and line probe assay-25. Research nurses used a cervical brush to collect samples of exfoliated cervical cells from all the study participants. Cox proportional hazards models were used to estimate associations between HIV and HPV infections. Results The mean age of the study participants was 38 (standard deviation, ± 8) years; 51% were HIV positive. The rate of clearing any HPV infection was 2.0% per month among all women in the study population, 2.5% per month among HIV-negative women, and 1.6% per month, among HIV-positive women. The clearance rate per 1,000 person-months of observation for any lrHPV infection and any hrHPV infection were 9.21 and 8.83, respectively, for HIV-negative women, and 9.38 and 9.37, respectively, for HIV-positive women. In multivariate models, the hazard ratios for HIV-positive compared with HIV-negative women were 0.85 (95% CI, 0.51 to 1.43; P = .55) and 0.95 (95% CI, 0.54 to 1.65; P = .85) for cleared infections with any lrHPV and any hrHPV, respectively. The hazard ratio for HIV-positive compared with HIV-negative women was 0.39 (95% CI, 0.17 to 0.88; P = .02) for cleared infections with any multiple HPV and 0.13 (95% CI, 0.03 to 0.58; P = .007) for cleared infections with multiple hrHPV. Conclusion In this study population, we observed that HIV-positive women were less likely to clear infections with multiple hrHPV types.

Indexed as

AdultCervix UteriFemaleHIVHIV InfectionsHumansPapillomaviridaePapillomavirus InfectionsRisk Factors

Identifiers

PMID30125130
PMCPMC6223532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.